“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

14 May 2019
Pharma

Visiongain has launched a new pharma report Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies.

The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. In 2018, Visiongain notes that Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 42.4% of the global IVD market with combined revenue of $29.3bn.

The lead analyst of the report commented "In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions. This has been done primarily in response to increased competition to maintain or increase market share, and to solidify a company’s position in the market. Small innovative companies are providing new technologies which feed into the development of products by leading players. Such companies represent potential acquisition targets for corporations seeking opportunities."

Leading companies featured in the report include Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher Corporation, Laboratory Corporation of America (LabCorp), QIAGEN, Roche, Siemens AG, Sysmex Corporation, Thermo Fisher Scientific and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Biobanking market set to grow to $4.2bn by 2024” says new Visiongain report

Biobanking infrastructure is improving at a global level with the establishment of large-scale national biobanks, population biobank projects, virtual biobanks and networking at national and international level.

23 May 2019

Read

“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs.

21 May 2019

Read

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1